R&D Expertise

CN EN

Innovation

Dedicated to R&D of Medicines for
Respiratory and Pediatric Diseases

RSV

Respiratory Syncytial Virus

Respiratory syncytial virus (RSV) is the most important viral pathogen causing acute lower respiratory tract infections in children under 5 years old worldwide, and it is the primary factor leading to hospitalization due to viral respiratory infections in infants and young children. It is estimated that there are approximately 33 million cases of RSV associated acute lower respiratory tract infection among children under the age of 5 globally, resulting in approximately 3.6 million hospitalizations and 100,000 deaths. Currently, there is no effective anti-viral treatment available for RSV.
IPF

Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disorder characterized by fibrosis of the lungs from an unknown cause. It is estimated that the number of people worldwide suffering from IPF increased from 1.4 million to 1.7 million between 2015 and 2022. IPF has an insidious onset, and the disease progresses continuously and irreversibly thereafter. The median survival time of patients is only 3-5 years, and the estimated five-year survival rate is about 20%, which is lower than many types of cancer. The existing therapies have limited effectiveness with poor tolerability and significant side effects (such as gastrointestinal intolerance, phototoxicity, and hepatotoxicity), which often lead to treatment discontinuation.
COPD

Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous lung condition characterized by chronic respiratory symptoms (dyspnea, cough, sputum production and/or exacerbations) due to abnormalities of the airways (bronchitis, bronchiolitis) and/or alveoli (emphysema) that cause persistent, often progressive, airflow obstruction.COPD patients are at high-risk for heart disease, lung cancer, and poor quality of life. In 2020, there were approximately 218 million COPD patients worldwide, of which around 114 million were in China. The incidence in China is expected to increase to 153 million patients by 2030. There is currently no cure for COPD, and existing therapy may only alleviate symptoms.
ADHD

Attention Deficit Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder (ADHD) is a common chronic neurodevelopmental disorder that begins in childhood and can continue into adult life. Its main features are attention deficit and/or hyperactive impulses that are not commensurate with developmental levels. It is estimated that the global prevalence of ADHD in children is about 7.2%, and in Chinese children and adolescents is 6.3%. While the overall prevalence of ADHD is high, the awareness of the condition is low and consultation rate for ADHD in children is under 10% in China.

Tel：+86-21-50681677
Address：No. 25, Lane 388, Shengrong Road, Pudong
New Area, Shanghai, China
E-mail：ir@arkbiosciences.com

Tel：+86-21-50681677
Address：No. 25, Lane 388, Shengrong Road, Pudong
New Area, Shanghai, China
E-mail：ir@arkbiosciences.com

Official account

        
HOME

TEL

TOP